| Literature DB >> 35147550 |
Laure Pauly1,2,3,4, Claire Pauly3,4, Maxime Hansen1,4, Valerie E Schröder3,4, Armin Rauschenberger3, Anja K Leist5, Rejko Krüger1,3,4.
Abstract
BACKGROUND: The analysis of the procedural memory is particularly relevant in neurodegenerative disorders like Parkinson's disease, due to the central role of the basal ganglia in procedural memory. It has been shown that anterograde procedural memory, the ability to learn a new skill, is impaired in Parkinson's disease. However, retrograde procedural memory, the long-term retention and execution of skills learned in earlier life stages, has not yet been systematically investigated in Parkinson's disease.Entities:
Keywords: Parkinson’s disease; cognitive impairment; habits; memory; neurodegenerative disorder; neuropsychology
Mesh:
Year: 2022 PMID: 35147550 PMCID: PMC9108589 DOI: 10.3233/JPD-213081
Source DB: PubMed Journal: J Parkinsons Dis ISSN: 1877-7171 Impact factor: 5.520
Fig. 1Representation of the CUPRO evaluation system, an extended evaluation system for the Cube Copying Test. The first intermediate score (IS1) evaluates the copying procedure, the second intermediate score (IS2) the visuo-constructive functions. A-D) Representation of the four copying procedures.
Demographic and clinical data for people with Parkinson’s disease (n = 201) and control subjects (n = 201)
| Descriptive statistics |
| ||||||
| Variable | PD ( | CS ( | PD vs. CS | ||||
|
|
|
|
|
|
| ||
| Gender, M / F | 111 / 90 | – | 109 / 92 | – | 0.920 | ||
| Handedness, R / L / A | 170 / 14/ 7+10na | – | 180/6/10+5na | – | 0.139 | ||
| Age, y | 64.84 | 10.20 | 22–87 | 64.71 | 10.18 | 30–86 | 0.943 |
| Education, y | 13.60 | 3.80 | 4–25 | 14.25 | 3.96 | 4–24 | 0.128 |
| MOCA total score (/30) | 26.58 | 2.68 | 21–30 | 26.97 | 2.29 | 21–30 | 0.246 |
| MDS-UPDRS-III (/132) | 32.80 | 13.40 | 7–88 | 4.59 | 5.10 | 0–27 | < 0.001*,** |
| Hoehn and Yahr | 2.06 | 0.53 | 0.00 | 0.00 | < 0.001*,** | ||
| Stage 1 / 1.5 / 2 / | 19 / 13 / 119 / 29 / | ||||||
| 2.5 / 3 / 4 / 5 | 18 / 2 / 0+1na | ||||||
| BDI-I (/63) | 8.32 | 6.36 | 0–34 | 4.95 | 4.72 | 0–27 | < 0.001*,** |
| SAS (/42) | 13.63 | 5.49 | 1–32 | 9.84 | 4.75 | 0–25 | < 0.001*,** |
| Languages spoken | 2.81 | 1.10 | 1–4 | 3.56 | 0.78 | 1–4 | < 0.001*,** |
| Disease duration, y | 5.37 | 4.39 | 0–24 | – | – | – | – |
| LEDD | 596.35 | 391.30 | 50–2062 | – | – | – | – |
SD, standard deviation; PD, people with Parkinson’s disease; CS, control subjects; M, male; F, female; R, right-handed; L, left-handed; A, ambidextrous; na, not available; n, sample size; MDS-UPDRS, Movement Disorder Society - Unified Parkinson’s Disease Rating Scale; BDI, Beck Depression Inventory; SAS, Starkstein Apathy Scale; MoCA, Montreal Cognitive Assessment; LEDD, Levodopa Equivalent Daily Dose. *Significant at the 5% level (2-tailed). **Significant at the Bonferroni-adjusted 5% level (p < = 0.05/10).
Cube Scoring according to the classical evaluation (evaluated with one point) and extended evaluation system of the cube (evaluated with six points; divided into two intermediate scores: IS1 (assesses retrograde procedural memory) and IS2 (assesses the visuo-constructive functions)
| Descriptive statistics |
| |||||
| Variable | PD ( | CS ( | PD vs. CS | |||
|
|
|
|
| |||
| Extended evaluation | IS1 (/3) | 2.05 | 1.13 | 2.43 | 0.90 | 0.008*,** |
| system of the Cube | IS2 (/3) | 2.26 | 1.10 | 2.59 | 0.84 | 0.013*,** |
| Copying Test | ||||||
| Classical evaluation score | % of participants |
|
| |||
| of the Cube Copying | with correct | 65.67 | 83.58 | < 0.001*,** | ||
| test (Nasreddine et al.) | result | |||||
| [ | ||||||
The Cube Copying total score (classical evaluation system) on one point evaluates the final result of the cube; one point is administered if the copy is identical to the model. In the extended evaluation system: the first intermediate score (IS1) evaluates the drawing procedure. The second intermediate score (IS2) evaluates visuo-constructive functions. SD, standard deviations; PD, participants with Parkinson’s disease; CS, control subjects; IS, intermediate score. *Significant at the 5% level (2-tailed). **Significant at the Bonferroni-adjusted 5% level (p < = 0.05/3).
Correlations for the Intermediate Scores 1 in the PD and the CS group
| Spearman Correlations | ||||||
| PD ( | CS ( | |||||
| Spearman –Correlation coefficient R |
| Spearman –Correlation coefficient R |
| |||
| Disease Duration | –0.093 | 0.216 | – | – | – | |
| MDS-UPDRS-III | –0.108 | 0.129 | –0.225 | * | 0.010 | |
| LEDD | +0.015 | 0.842 | – | – | – | |
| Education | +0.224 | *, ** | 0.002 | +0.106 | 0.135 | |
| MoCA total score | +0.364 | *a, ** | < 0.001 | +0.203 | * | 0.004 |
| Age | –0.228 | *a | 0.001 | –0.006 | 0.931 | |
| BDI-I | –0.128 | 0.075 | –0.060 | 0.404 | ||
| SAS | –0.189 | * | 0.009 | –0.092 | 0.201 | |
| Hoehn and Yahr | –0.150 | * | 0.035 | – | – | – |
| PDQ-39 | –0.173 | * | 0.018 | – | – | – |
PD, people with Parkinson’s disease; CS, vontrol subjects; UPDRS, Unified Parkinson’s Disease Rating Scale; LEDD, Levodopa Equivalent Daily Dose; MoCA, Montreal Cognitive Assessment; BDI, Beck Depression Inventory; SAS, Starkstein Apathy Scale; PDQ-39, Parkinson’s Disease Questionnaire –39 items. *Significant at the 5% level (2-tailed). *aSignificant at the 1% level (2-tailed). **Significant at the Bonferroni-adjusted 5% level (p < = 0.05/16).